Loss of PTEN leads to activation of the PI3K/AKT/mTOR pathway, then promotes the proliferation and progression of DLBCL, and shortens the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL. This evidence concerns the gene PTEN and diffuse large B-cell lymphoma.